GSK is expanding its partnership with Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKEX: 1177), by granting the company China commercialization rights for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) and Anoro Ellipta (umeclidinium/vilanterol; UMEC/VI).
The agreement extends the companies' May 2026 collaboration around the hepatitis B candidate bepirovirsen into respiratory medicine, creating a multi-product partnership spanning two therapeutic areas. Trelegy and Anoro generated combined global sales of GBP 3.54 billion (approximately USD 4.5 billion) in 2025.
Financial terms were not disclosed. Under the agreement, CTTQ will purchase finished product from GSK and book China sales revenue, following the same commercialization and supply model used in the earlier bepirovirsen collaboration.
Why it matters
The deal follows Trelegy's 2026 China approval in asthma, expanding the product beyond its existing COPD indication. With more than 100 million COPD patients and approximately 50 million asthma patients, China represents one of the world's largest respiratory markets, while recent public health initiatives are expected to improve diagnosis and treatment rates.
For CTTQ, the products strengthen a respiratory franchise that already includes one of China's largest innovative pipelines, providing established brands, physician access, and commercial infrastructure ahead of future launches from its internal portfolio.
Deal structure
The agreement differs from many multinational commercialization deals in China. Rather than paying royalties or sharing profits, CTTQ will purchase product from GSK under agreed transfer pricing and recognize sales as its own revenue.